Insider Selling: Emergent Biosolutions (NYSE:EBS) SVP Sells $19,590.00 in Stock

Emergent Biosolutions Inc. (NYSE:EBS) SVP Paul Williams sold 3,000 shares of the firm’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $6.53, for a total transaction of $19,590.00. Following the completion of the transaction, the senior vice president directly owned 156,098 shares of the company’s stock, valued at $1,019,319.94. This represents a 1.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Emergent Biosolutions Price Performance

Shares of EBS opened at $7.08 on Thursday. The company has a current ratio of 5.42, a quick ratio of 2.95 and a debt-to-equity ratio of 1.70. The company’s fifty day simple moving average is $6.09 and its 200 day simple moving average is $7.47. Emergent Biosolutions Inc. has a 1-year low of $4.36 and a 1-year high of $14.06. The company has a market cap of $362.94 million, a price-to-earnings ratio of -1.99 and a beta of 2.28.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.68. Emergent Biosolutions had a negative net margin of 22.95% and a positive return on equity of 16.35%. The firm had revenue of $234.30 million during the quarter, compared to analysts’ expectations of $177.50 million. On average, research analysts forecast that Emergent Biosolutions Inc. will post 0.13 earnings per share for the current fiscal year.

Institutional Trading of Emergent Biosolutions

Several institutional investors have recently added to or reduced their stakes in EBS. WINTON GROUP Ltd increased its position in Emergent Biosolutions by 243.2% during the 2nd quarter. WINTON GROUP Ltd now owns 45,744 shares of the biopharmaceutical company’s stock worth $383,000 after buying an additional 32,415 shares during the period. Integrated Wealth Concepts LLC bought a new stake in shares of Emergent Biosolutions in the second quarter valued at about $29,000. Ancora Advisors LLC boosted its position in shares of Emergent Biosolutions by 160.9% in the second quarter. Ancora Advisors LLC now owns 1,067,867 shares of the biopharmaceutical company’s stock valued at $8,949,000 after acquiring an additional 658,600 shares during the period. Public Employees Retirement System of Ohio acquired a new position in shares of Emergent Biosolutions in the second quarter valued at about $36,000. Finally, Bank of America Corp DE acquired a new position in shares of Emergent Biosolutions in the second quarter valued at about $1,276,000. 78.40% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

EBS has been the subject of a number of recent analyst reports. Zacks Research raised Emergent Biosolutions to a “hold” rating in a research report on Tuesday, August 11th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Emergent Biosolutions in a report on Wednesday, September 9th. JPMorgan Chase & Co. assumed coverage on shares of Emergent Biosolutions in a research report on Friday, August 21st. They set an “underweight” rating for the company. Finally, Weiss Ratings upgraded shares of Emergent Biosolutions from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, August 21st. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $10.00.

About Emergent Biosolutions

Emergent BioSolutions Inc (NYSE:EBS) is a life sciences company focused on developing, manufacturing and supplying medical countermeasures for public health threats, including chemical, biological, radiological and nuclear hazards, as well as infectious diseases. The company serves government agencies, healthcare providers and commercial customers.

Emergent’s portfolio has included vaccines, therapeutics and other products used to prevent or treat serious health threats. Its offerings include BioThrax, an anthrax vaccine, and ACAM2000, a smallpox vaccine, along with products such as botulism antitoxin and vaccinia immune globulin.